Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2307PDF: 1846HTML: 847 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
3014PDF: 1413HTML: 3727Untitled: 219Untitled: 229Untitled: 203 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
882PDF: 138HTML: 222 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
578PDF: 283HTML: 123 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1170PDF: 1222Suppl. Files: 589HTML: 99 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1368PDF: 1124HTML: 256 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1539HTML: 658PDF: 885 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3925PDF: 1729HTML: 11847Figures Haase: 239 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3467PDF: 2047HTML: 7575 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2073PDF: 785HTML: 724Table1: patient's characteristics: 179Table 2: profile of each patient: 201 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2575HTML: 310PDF: 949 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3753PDF: 1269HTML: 5092Incidence age-standardized rates for HL across the Mediterranean basin: 236 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3375PDF: 1763HTML: 1170 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2677PDF: 846HTML: 5378 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9354PDF: 6215HTML: 88096Fig.1b: 224Fig.1c: 224Fig.2a: 207Fig.2b: 206Fig.4: 228Fig.2c: 208Fig.3: 210Tab.1: 265Tab.2: 245Tab.3: 227Tab.4: 256Fig1a: 222 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1671PDF: 1112HTML: 483 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3730PDF: 2605HTML: 1637 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3803PDF: 939HTML: 6880 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
3181PDF: 1087HTML: 296Suppl. Files: 531 -
SOLITARY PLASMACYTOMA
4203PDF: 2248HTML: 1406fIGURES 1,2: 256 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3767PDF: 1733HTML: 2697 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2290PDF: 1671HTML: 615 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3203PDF: 928HTML: 7307Kost Fig1: 214Kost Fig 2: 200Kost Fig3: 207Kost Fig 4: 219Kost Fig5: 217Kost fig 6: 204 -
-
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4143PDF: 1581HTML: 9308Untitled: 308Untitled: 206Untitled: 193Untitled: 190Untitled: 207Untitled: 366 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2576PDF: 824HTML: 1747 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2864PDF: 1194HTML: 3312 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4064PDF: 1100HTML: 3900Untitled: 190Cneo. Fig.1: 128Untitled: 123Untitled: 148Untitled: 157 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2988PDF: 1057HTML: 5644 -







